ASTH vs OSCR vs ALHC vs CLOV

For growth investors, Astrana Health, Inc.

(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 27. 5% for Oscar Health, Inc. (OSCR). Astrana Health, Inc. (ASTH) offers the better valuation at 85. 4x trailing P/E (31. 0x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Oscar Health, Inc.

is actually cheaper at 26. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Astrana Health, Inc.

(ASTH) delivered a total return of +13. 6%, compared to -62. 2% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ASTH returned +678. 2% versus CLOV's -69. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alignment Healthcare, Inc.

(ALHC) is the lower-risk stock at 0. 81β versus Oscar Health, Inc. 's 1. 83β — meaning OSCR is approximately 128% more volatile than ALHC relative to the S&P 500. On balance sheet safety, Oscar Health, Inc. (OSCR) carries a lower debt/equity ratio of 44% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Astrana Health, Inc.

(ASTH) is pulling ahead at 56. 4% versus 27. 5% for Oscar Health, Inc. (OSCR). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Astrana Health, Inc.

(ASTH) is the more profitable company, earning 0. 7% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ASTH leads at 2. 5% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Oscar Health, Inc.

(OSCR) trades at 26. 7x forward P/E versus 101. 8x for Alignment Healthcare, Inc. — 75. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 38. 5% to $24. 83.

In this comparison, ASTH (0.

4% yield) pays a dividend. OSCR, ALHC, CLOV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Astrana Health, Inc.

(ASTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +678. 2% 10Y return). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ASTH: +678. 2%, OSCR: -38. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.